A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Doctors want to test a new medicine called CC-95266 to see if it can safely and helpfully treat people with a certain type of blood cancer called relapsed and/or refractory multiple myeloma (R/R MM).
Doctors want to test a new medicine called CC-95266 to see if it can safely and helpfully treat people with a certain type of blood cancer called relapsed and/or refractory multiple myeloma (R/R MM).
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: